Are night sweats and visual hallucinations adverse effects of quetiapine (Seroquel)?

Yes, Both Night Sweats and Visual Hallucinations Are Recognized Adverse Effects of Quetiapine (Seroquel)

Both night sweats and visual hallucinations can occur with quetiapine, though they manifest through different mechanisms and with varying frequencies.

Night Sweats (Diaphoresis/Sweating)

Night sweats are a documented adverse effect of quetiapine. The FDA label explicitly lists sweating as an adverse reaction occurring in clinical trials 1. Additionally, guidelines note that diaphoresis (excessive sweating) is a manifestation of autonomic dysfunction that can occur with antipsychotic medications 2.

• In the ESMO delirium guidelines, sweating is mentioned as a potential adverse effect when quetiapine is used at 25 mg doses 3
• The mechanism relates to quetiapine's effects on autonomic nervous system regulation
• This side effect can occur at both low and therapeutic doses

Clinical approach: If night sweats are bothersome, consider dose reduction first. If symptoms persist despite dose adjustment, switching to an alternative atypical antipsychotic with less autonomic effects (such as aripiprazole) may be warranted.

Visual Hallucinations

Visual hallucinations present a more complex clinical picture with quetiapine:

Paradoxical Effect

Quetiapine is actually indicated for treating hallucinations in conditions like schizophrenia and delirium 4, 3. However, paradoxically, there is emerging evidence that quetiapine itself may induce psychotic symptoms in some patients:

• A 2024 case report describes quetiapine-induced psychosis in a previously psychosis-naive patient, with symptom resolution after switching to ziprasidone 5
• The FDA label does not specifically list visual hallucinations as a common adverse effect in the standard adverse reaction tables 1
• Guidelines note that antipsychotics themselves can cause "increased patient agitation and delirium" 3

Important Differential Considerations

Before attributing visual hallucinations to quetiapine, rule out:

1. Underlying psychiatric condition progression - The primary disorder may be worsening
2. Delirium from other causes - Medical illness, metabolic disturbances, other medications
3. Substance use - Particularly if there is concurrent alcohol or drug use
4. Neuroleptic malignant syndrome (NMS) - Though rare, altered mental status is a cardinal feature 2
5. Inadequate dosing - Subtherapeutic doses may not adequately control psychotic symptoms

Clinical Decision Algorithm

If visual hallucinations develop on quetiapine:

1. First: Assess timing - Did hallucinations begin after starting quetiapine or represent inadequate symptom control?
2. Second: Rule out medical causes of delirium (infection, metabolic derangement, hypoxia)
3. Third: Review all medications for anticholinergic burden - quetiapine has moderate anticholinergic activity 6
4. Fourth: If dose is subtherapeutic (<150 mg/day for psychosis), consider increasing to therapeutic range
5. Fifth: If dose is adequate and hallucinations are new/worsening, consider switching to another atypical antipsychotic with lower anticholinergic activity (such as risperidone or aripiprazole)

Additional Safety Considerations

Both symptoms warrant attention to quetiapine's broader adverse effect profile:

• Orthostatic hypotension is common and may contribute to autonomic symptoms 4, 3
• Sedation occurs frequently (18-57% depending on indication and dose) 1
• Metabolic effects including weight gain and glucose/lipid abnormalities require monitoring 6
• Cognitive effects including sedation and potential cognitive blunting 7

Monitor baseline and periodically: Blood pressure (especially orthostatic), weight, metabolic parameters, and mental status 6.

Common Pitfall to Avoid

Do not assume all new psychiatric symptoms on quetiapine represent treatment failure of the underlying condition. Consider medication-induced effects, particularly if symptoms are atypical for the patient's baseline presentation or emerged temporally related to quetiapine initiation/dose changes.